Intuitive Surgical, Inc. (NASDAQ:ISRG) Stake Lessened by Sylvest Advisors LLC

Sylvest Advisors LLC lowered its position in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 41.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,729 shares of the medical equipment provider's stock after selling 1,246 shares during the period. Intuitive Surgical comprises approximately 0.5% of Sylvest Advisors LLC's holdings, making the stock its 29th largest position. Sylvest Advisors LLC's holdings in Intuitive Surgical were worth $856,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Brighton Jones LLC lifted its position in shares of Intuitive Surgical by 24.9% during the 4th quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider's stock valued at $1,916,000 after acquiring an additional 731 shares during the period. Bank Pictet & Cie Europe AG increased its stake in Intuitive Surgical by 0.5% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 190,969 shares of the medical equipment provider's stock valued at $99,678,000 after purchasing an additional 883 shares in the last quarter. Wealthspire Advisors LLC raised its holdings in Intuitive Surgical by 28.6% during the fourth quarter. Wealthspire Advisors LLC now owns 1,645 shares of the medical equipment provider's stock worth $859,000 after purchasing an additional 366 shares during the last quarter. MONECO Advisors LLC boosted its position in Intuitive Surgical by 8.1% during the fourth quarter. MONECO Advisors LLC now owns 1,129 shares of the medical equipment provider's stock worth $589,000 after purchasing an additional 85 shares in the last quarter. Finally, World Equity Group Inc. grew its holdings in Intuitive Surgical by 22.8% in the fourth quarter. World Equity Group Inc. now owns 512 shares of the medical equipment provider's stock valued at $267,000 after purchasing an additional 95 shares during the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Stock Up 2.4%

Shares of NASDAQ ISRG traded up $12.56 during trading on Thursday, hitting $534.19. 1,965,145 shares of the company traded hands, compared to its average volume of 1,672,340. The firm has a market capitalization of $191.46 billion, a P/E ratio of 78.33, a P/E/G ratio of 5.53 and a beta of 1.67. The company has a 50-day moving average price of $530.03 and a 200-day moving average price of $536.86. Intuitive Surgical, Inc. has a 1 year low of $413.82 and a 1 year high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 EPS for the quarter, topping the consensus estimate of $1.71 by $0.10. The company had revenue of $2.25 billion during the quarter, compared to analyst estimates of $2.19 billion. Intuitive Surgical had a return on equity of 14.43% and a net margin of 28.41%. During the same period in the prior year, the firm posted $1.50 earnings per share. Research analysts predict that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on ISRG shares. Piper Sandler decreased their price objective on shares of Intuitive Surgical from $670.00 to $575.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 23rd. Citigroup reiterated a "buy" rating and issued a $650.00 price target (up from $590.00) on shares of Intuitive Surgical in a research report on Thursday, May 22nd. Barclays cut their price objective on Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating for the company in a research report on Thursday, April 24th. Truist Financial reduced their target price on Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd. Finally, Deutsche Bank Aktiengesellschaft downgraded Intuitive Surgical from a "hold" rating to a "sell" rating and dropped their price target for the stock from $515.00 to $440.00 in a research report on Monday, June 9th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat.com, Intuitive Surgical currently has an average rating of "Moderate Buy" and a consensus price target of $588.95.

Insider Activity at Intuitive Surgical

In other news, EVP Gary Loeb sold 1,700 shares of Intuitive Surgical stock in a transaction that occurred on Friday, April 25th. The shares were sold at an average price of $513.18, for a total transaction of $872,406.00. Following the sale, the executive vice president now owns 2,245 shares in the company, valued at $1,152,089.10. This trade represents a 43.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Mark Brosius sold 216 shares of the firm's stock in a transaction on Friday, June 6th. The shares were sold at an average price of $563.11, for a total transaction of $121,631.76. Following the sale, the senior vice president now directly owns 907 shares of the company's stock, valued at approximately $510,740.77. The trade was a 19.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 4,998 shares of company stock worth $2,611,577. Company insiders own 0.70% of the company's stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.